(HealthDay News) — During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company’s high prices for its blockbuster ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

Editorial writers delve into these public health issues.

Novo Nordisk CEO Lars Fruergaard Jørgensen faced Senate scrutiny over the high prices of Wegovy and Ozempic as U.S. demand ...

Novo Nordisk CEO Lars Fruergaard Jorgensen testified before the Senate Health, Education, Labor and Pensions Committee hearing in ...

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...

WASHINGTON—U.S. Senator Mike Braun questioned Novo Nordisk CEO, Lars Fruergaard Jørgensen, at the Senate Health, Education, ...

Cantor Fitzgerald Managing Director Louise Chen noted that price of weight loss drugs from Novo Nordisk and Eli Lilly should ...

Novo Nordisk said it’s open to discussions with PBMs based on their commitments that a lower semgalutide list price would not ...

Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal ...

U.S. Sen. Bernie Sanders said major PBMs have agreed not to limit coverage of Ozempic and Wegovy if Novo lowers its prices.

Novo Nordisk's top executive faced a Senate grilling on Tuesday over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars in the ...